嵌合抗原受体 T 细胞 (CAR-T) 疗法已成为一种突破性且极具前景的癌症治疗方法。本文回顾了CAR-T疗法在治疗各种血液恶性肿瘤方面的疗效，并提到了其对尚未获得FDA批准的实体瘤的作用。本文还讨论了不同的常见和不常见副作用，并分别关注每种药物的效果。通过回顾 FDA 对 CAR-T 疗法研究的建议，我们广泛讨论了剂量限制性毒性。这进一步凸显了对精确剂量策略的需要，在治疗益处和潜在风险之间取得平衡。此外，我们还回顾了接受 CAR-T 治疗的患者的长期随访，以获得有关反应持久性和迟发效应的宝贵见解。版权所有 © 2024 作者。由 Elsevier B.V. 出版。保留所有权利。

Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a groundbreaking and highly promising approach for the management of cancer. This paper reviews the efficacy of CAR-T therapy in the treatment of various hematological malignancies, also, with a mention of its effect on solid tumors, for which they have not received FDA approval yet. Different common and uncommon side effects are also discussed in this paper, with attention to the effect of each drug separately. By reviewing the recommendations of the FDA for CAR-T therapy research, we have extensively discussed dose-limiting toxicities. This further highlights the need for precise dosing strategies, striking a balance between therapeutic benefits and potential risks. Additionally, we reviewed the long-term follow-up of patients receiving CAR-T therapy to gain valuable insights into response durability and late-onset effects.Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.